Embedded Files
Wikipedia 🌐 NONE
Wikipedia 🌐 NONE
ASSOCIATIONS
ASSOCIATIONS
DynPort Vaccine Company, LLC ( ... )
2007 (June 4) - Santa Maria Times
2007 (June 4) - Santa Maria Times
Jill Glasspool - mother is Iris Glasspool ... https://www.newspapers.com/image/446603472/?terms=%22jill%20glasspool%22&match=1
2007-06-13-santa-maria-times-pg-e6.jpg
2007-06-13-santa-maria-times-pg-e6-clip-glasspool.jpg
Directory info (1986 to 2020)
Directory info (1986 to 2020)
Name : Jill Glasspool Malone
Birth Date : Nov 1960
Residence Date : 1986-2020 : Address : 771 Mitchell Rd / Jasper, Georgia, USA / 30143
Second Residence Date : 2016-2020 : 2981 Zion Rd / Troy, Virginia, USA / 22974
Third Residence Date : 2014-2016 : 10029 Hatton Ferry Rd 1 / Scottsville, Virginia, USA / 24590
Fourth Residence Date : 2002-2007 : 4752 Broad Run Rd / Jefferson, Maryland, USA / 21755
About
About
Dr. Glasspool Malone is a specialist in preclinical, regulatory, and clinical project management, with special expertise in public policy and Federal regulatory issues. She has been a co-founder of a number of biotech companies and has held positions in the biotechnology industry and academia. She has an extensive publication record in gene therapy, DNA and RNA vaccines, immunology and public policy for infectious disease outbreaks.
She graduated from University of California, San Diego with a bachelor’s degree specializing in behavioral anthropology (the study of the behavior of animals and how they relate to humans). She did her graduate coursework at UC Davis in comparative pathology and graduated Union Institute and University with a PhD in Public Policy, with an emphasis on Biotechnology. In 2016, she graduated from the post-doctoral Harvard Medical School Global Clinical Scholars program.She has serve(d) on numerous non-profit boards.
Jill is passionate about her work and thrives on helping the world be a better and safer place for all.
Dr. Glasspool Malone lives in Virginia with her beloved husband on a horse farm, where they breed and train Lusitano horses. Jill is an avid horse person and a horse show judge for equine disciplines.
Her favorites things to do outside of work are ride horses, train, teach and judge classical dressage and working equitation. Her other passion is travel.
Her goals are to create the best analytics and consulting firm in the bio-sector possible.
Specialties: Jill Glasspool Malone, PhD consults in clinical trials management, research, due-diligence, and proposal development. She is involved in corporate management, business development as well as consulting. She is an experienced author and available for consultation.
Companies
Companies
RW Malone MD, LLC (Total Duration: 20 yrs, 4 months [as of August 2021] )
Title : President, analyst and consultant ( Oct 2007 – Present [Aug 2021] )
Employment Duration : 14 yrs
Location : Troy, VA
Dr. Glasspool Malone has experience in preclinical, regulatory, and clinical project management, with special expertise in public policy and Federal regulatory issues. Dr. Glasspool has held supervisory and management positions in the biotechnology industry and academia. She has an extensive publication record. Jill Glasspool Malone, PhD is is involved in business development as well as research, analytics and consulting.
Title : President (Jun 2001 – [Oct 2007] )
Location : Madison, VA
Atheric Pharmaceutical LLC
Title : Vice President ( Feb 2016 – Jan 2017 )
Employment Duration : 1 yr
Location : Troy, VA
Atheric Pharmaceutical LLC ("Atheric(tm)") is a biopharmaceutical company focused on the rapid development and commercialization of re-purposed drugs to prevent and treat Zika and other Flavivirus disease. Atheric is committed to providing broad-spectrum medical countermeasures for Zika and other neglected tropical diseases.
Zika outbreak medical countermeasure (MCM) strategies have been identified, with the most promising MCM available for expedited clinical testing identified being re-purposed anti-malarial drugs. Of these, the most suitable for immediate clinical testing for use in protecting against the Zika Virus infection; to prevent development of Zika Virus fetal syndrome and GBS have been identified. Provisional patents covering the used of these compounds for Zika and other Flaviviruses have been filed with the US Patent and Trademark Office. Clinical trials to determine correct dosing and proprietary formulations appropriate for the indicated therapies are being rapidly developed. Regulatory discussions with FDA have been initiated.
Zika virus has been postulated as playing a key role in the pathogenesis of Zika-associated primary microcephaly and GBS. The anti-malarial drugs under pending patents are autophagy inhibitors, and in vitro testing has demonstrated efficacy. Of interest is that these drugs have been safely used during pregnancy, and cross the placenta enabling clinically significant pharmacodistribution to both mother and fetus. Systemic literature review with meta-analysis indicates that prenatal exposure to these drugs during maternal autoimmune disease treatment does not appear to increase the risk of adverse pregnancy outcomes, except those associated with the underlying disease.
Gene Delivery Alliance, Inc
Title : Consulting and founder (2001 – 2005 )
Employment Duration : 4 yrs
Dept. of Surgery, USUHS [ "Uniformed Services University of the Health Sciences" ]
Title: Senior Research Associate ( 2000 – 2001 )
Employment Duration : 1 yr
Location : Rockville, MD
Intradigm, Corp
Title : Co-Founder, Board of Director Member and Secretary of the board ( 1999 – 2001 )
Employment Duration : 2 yrs
Intradigm was merged with Silence Therapeutics, taking the Silence Therapeutics name -which is a leading RNA therapeutics company and publicly traded.
University of Maryland Medical School
Title : Senior Research Associate ( 1997 – 2000 )
Employment Duration : 3 yrs
Location : Baltimore, Md
UC Davis
Title : Research Specialist ( 1992 – 1996 )
Employment Duration : 4 yrs
Location : Davis, CA
Laboratory manager and supervisor
Immunology, cell culture (cell lines/primary, CTL and T cell proliferation assays), gene transfer, genetic vaccination research, animal research (mouse, rat, pig, primate) BSL2 work
Extensive laboratory skills
Laboratory and employee supervisory.
Managed laboratory regulatory needs including IACUC, radiation safety, biosafety, OSHA
Grant writing, budget writing, budget supervision, IACUC protocol writing.
Animal research, including non-human primates. Procedures, surgery, quality control, etc.
Writing papers for publication (see attached list)
Education
Education
Harvard Medical School
Degree Name : Global Clinical Scholar
Field Of Study : Global Clinical Scholars Research Training Program
Grade : Post Doctoral
Dates attended or expected graduation : 2015 – 2016
The Harvard Medical School Global Clinical Scholars Research Training (GCSRT) Program provides clinicians and clinician-scientists advanced training in the methods and conduct of clinical research. The 2015 - 2016 program begins on June 13, 2015, and ends on June 4, 2016.
All participants who achieve the program objectives are granted a Certificate of Completion, and will be eligible to become Associate Members of the Harvard Medical School and Harvard University Alumni Association.
The Union Institute and University
Degree Name : Doctor of Philosophy (PhD)
Field Of Study : Public Policy/Administration and a Specialization in Biotechnology
Dates attended or expected graduation : 2001 – 2005
[Notes : from https://web.nkychamber.com/Education-Educational-Services/Union-Institute-University-4196 : A premier adult distance learning center offering nontraditional degree programs, adult online degrees, online bachelor's degrees and low residency degrees. ]
University of California, Davis
Degree Name : Graduate school
Field Of Study : Comparative Pathology
Dates attended or expected graduation : 1994 – 1996
UCSD
Degree Name : Bachelor's degree
Field Of Study : Anthropology
Dates attended or expected graduation : 1986 – 1989
with an emphasis in behavioral Anthropology
Volunteer experience
Volunteer experience
CONFEDERATION FOR WORKING EQUITATION : Board Member
Dates volunteered : Dec 2016 – Oct 2020 ( 3 yrs 11 mos )
Cause : Education
US Lusitano : Co-founder and board of director member
Dates volunteered : Jul 2019 – Present ( 2 yrs 3 mos [as of the date of this capture] )
Cause : Education ( The US Lusitano Association (USLA) is a sister organization of the Associação Portuguesa de Criadores do Cavalo Puro Sangue Lusitano. The organization registers PSL Lusitanos in the USA for the APSL and its mission is to preserve and protect this rare breed, as well as educate the public about the Lusitano. The oldest saddle breed in the world. )
https://opencorporates.com/companies/us_de/3382079
2021-09-04-opencorporates-com-companies-us-de-gene-delivery-alliance-3382079.pdf
2021-09-04-opencorporates-com-companies-us-de-gene-delivery-alliance-3382079-img-1.jpg
2021-09-06-facebook-jill-glasspool-malone-facebook-nov-2020-to-sep-6-2021-video-capture.mp4
2021-09-06-facebook-jill-glasspool-malone-facebook-nov-2020-to-sep-6-2021-video-capture-compressed.mp4
https://pubmed.ncbi.nlm.nih.gov/33833683/ 2021 (March 23) - "COVID-19: Famotidine, Histamine, Mast Cells, and Mechanisms" <-- Garcia-Sastre
https://web.archive.org/web/20170714055404/http://www.atheric.com/team
2017 - Atheric Pharma "team" page
2017-07-atheric-pharmaceutical-llc-about-page-form-web-archive-org.png
Atheric Leadership:
Robert W. Malone, M.D., M.Sci. CEO, CSO, co-founder and board of manager member of Atheric Pharmaceutical, LLC. Dr. Malone has extensive research and development experience in the areas of clinical trials, vaccines, gene therapy, bio-defense, and immunology. He has over twenty years of management and leadership experience in the academia, pharmaceutical and biotechnology industries. His FDA, HHS, and DoD agency knowledge is extensive. Dr. Malone is an internationally recognized scientist and is known as one of the original inventors of “DNA Vaccination.” Dr. Malone holds numerous fundamental domestic and foreign patents in the fields of gene delivery, delivery formulations, and vaccines. He has over fifty peer-reviewed publications, has been an invited speaker at over thirty-five conferences, has chaired numerous conferences and he has sat on numerous study sections. Dr. Malone is in the Harvard Medical School Global Clinical Scholars Program in 2015-2016.
In August 2014, colleagues at the Department of Defense/Defense Threat Reduction Agency asked Dr. Malone to step in and help NewLink manage the Ebola project and develop the contracts necessary to move the "orphan" PHAC/rVSV ZEBOV vaccine forward quickly. Dr. Malone got the project on track, recruited our client Focus Clinical Trials to team with USAMRIID/WRAIR to develop the immunoassays, put WHO leadership in touch with Pentagon leadership to expedite the initial WRAIR clinical trials, recruited the government of Norway to help fund the clinical research, used social media (LinkedIn) to recruit Merck Vaccines to join the project, recruited a management team, and lead the development of the BARDA and DTRA contracts - yielding over 200M$ in resources. Those were frightening times, but now we have a remarkably effective vaccine, developed in record time.
Dr. Malone was CEO and co-founder of RW Malone MD, LLC, a very successful consulting and development firm focused on clinical trials and USG medical countermeasure proposal capture and management. As a capture and proposal manager, Dr. Malone has an extraordinary funding record. In the past five years, he has been involved in ten billion dollars of successful government contracts and awards. A link to the PDF list of those awards, as well as details of his role in capturing those awards can be found below.
Dr. Jill Glasspool Vice President, Pre-clinical research and External Relations and board of manager member. Dr. Glasspool is an entrepreneurial executive. She is a co-founder of two biotech companies that have gone public and has held key early management positions in those companies, as well as others. She has a successful track record of leading bench and discovery research, protocol development, clinical research and clinical trials management. Her experience in preclinical, regulatory, and clinical project management, with particular depth in public policy and federal regulatory affairs is extensive. Dr. Glasspool has held supervisory and management positions in the biotechnology industry as well as academia. Significant expertise with federal contracting, grants, proposal development, business-to-business solutions, international NGO health related research and development allowed her to help build RW Malone MD, LLC into a successful venture, one that has been able to procure almost 10 billion in federal contracting dollars for clients. She is skilled in fostering a culture of innovative problem solving.
Dr. Glasspool’s scientific expertise includes clinical development, public administration, regulatory affairs, project management, cell based influenza, biodefense, vaccines, gene delivery and transfer, tissue and cell culture, DNA vaccination and other related scientific research. She has an extensive peer reviewed publication record, attended the University of California, San Diego and the University of California, Davis and most recently received postgraduate training as a Harvard Medical School Global Clinical Scholar in 2015-2016.
Patricia Hommel, Business Development. Ms. Hommel is experienced in both private and government sectors. She managed the business development program at the Chesapeake Innovation Center (CIC), America’s first business accelerator for government and homeland/national security initiatives, created to connect innovation with Homeland Security and Intelligence Community. Ms. Hommel scouted technology innovations and solutions for NSA, Northrop Grumman, Boeing and ARINC, and then prepared selected companies to meet with these CIC partners to expedite business alliances, procurement and funding opportunities. Ms. Hommel was Business Development Manager for a marketing and financial firm where she strengthened and increased the client base and revenues. She also managed client business initiatives to identify and develop opportunities and build strategic alliances such as assisting small businesses in getting on the GSA schedule. While developing a technology project for managing assets, she was chosen by Virginia’s Center for Innovative Technology as an emerging technology company.
Diego Mezzogiorno, "Specialist in International Affairs, Vice-President of the Chamber of Commerce and Industry Italy-South of Brazil. He worked with the World Bank through the Secretariat of Economic Development of the State of Santa Catarina in Brazil. Currently works on the technology and energy sector as a consultant to the UN in the UNDP (United Nations Development Programme) bringing renewable energies to the countryside.
Atheric Pharmaceutical LLC, Advisory Board: The Atheric advisory board is a mix of business, law and science experts who help guide Atheric leadership. Meetings are held quarterly, as well as on an informal basis.
James D. Talton, Ph.D. President & CEO of Alchem Laboratories (5/16 to Present), Dr. Talton was the CEO of Nanotherapeutics (1999-2016) and grew company to >$100m revenues/yr and 200 employees. Dr. Talton led proposal team and negotiations of>$1 billion in DoD and HHS contracts in last 5 years.
Discovering and Developing Re-purposed antiviral Drugs for Treatment and Prevention of Zika
The development of new antiviral drugs to combat disease is one of the most exciting areas of discovery medicine in the 21st century. In the last two decades, antiviral drugs have become a mainstay of modern medicine. Drugs are now available to treat diseases caused by many different viruses, including influenza, HIV, herpes, hepatitis B and hepatitis C. According to the World Health Organization, antiviral drugs for HIV have saved almost eight million lives over the last fifteen years. For infectious disease outbreaks, antiviral drugs may be the safest and least expensive treatment or prophylactic option.
Atheric has a rich and diverse pipeline of drugs with activity against:
Flaviviruses (Zika, Yellow Fever, others).
Alphaviruses (VEE, Chikungunya, others)
Atheric Pharmaceutical researchers have discovered that when repurposed drugs with different mechanisms of action are combined, they are much more effective at inhibiting viral infection, including infection by mosquito-transmitted viruses. Some anti-viral drug combinations have a synergistic effect, which greatly increases the likelihood of success in inhibiting arbovirus replication and spread. Some of these antiviral drug combinations are also toxic to the mosquitos which spread the virus. These benefits are likely to translate to shorter duration of infection, decreased viral load and, in the case of administering the drugs as a prophylactic, more likelihood of an individual not acquiring the disease. Obviously, this is very powerful strategy for combating the ongoing outbreaks of Zika virus, Chikungunya, and Yellow Fever virus infections.
The development of new antiviral drugs to combat disease is one of the most exciting areas of discovery medicine in the 21st century. In the last two decades, antiviral drugs have become a mainstay of modern medicine. Drugs are now available to treat diseases caused by many different viruses, including influenza, HIV, herpes, hepatitis B and hepatitis C. According to the World Health Organization, antiviral drugs for HIV have saved almost eight million lives over the last fifteen years. For infectious disease outbreaks, antiviral drugs may be the safest and least expensive treatment or prophylactic option.
The relatively high mutation rate associated with Zika is similar to that of other RNA viruses, and predicts rapid evolution to escape evolutionary pressure from drug monotherapies. Therefore, it is most appropriate to focus on developing multidrug therapy regimens that combine or cycle active drugs with different mechanisms of action. These drugs should ideally have minimal pharmacokinetic interactions and be safe when cycled or combined.
The Benefits of Re-purposed Drugs
One of the most exciting new approaches for drug development is finding new uses for currently marketed drugs. This process provides the quickest possible transition from research to approved drugs that physicians can prescribe and patients can use. “Re-purposed�? drugs already have a well-known clinical safety profile, which can avoid the lengthy regulatory hurdles and toxicology testing requirements that are needed for new drugs.
With careful selection criteria, testing drugs in combination using a high throughput system and pharmacometric modeling strategies, Atheric has been able to rapidly test and identify many antiviral drugs, which are active against Zika. This innovative approach truly has the potential to revolutionize how new antiviral drugs are discovered.
Why Not a Vaccine for Zika?
Vaccines are a great choice for many infectious diseases, but vaccines are time consuming to develop and pose safety risks for some types of infections, including a Zika virus infection. A recent report by the National Center for Biotechnology Information (NCBI) at the National Institutes of Health estimates that an extremely accelerated pathway for vaccine approval is 8-10 years. For example, the West Nile Vaccine that the Director of National Institute of Allergy and Infectious Diseases (NIAID) promised the US Congress in 2002 would be ready within three years, is just finishing up phase I clinical trials 14 years later.
Infectious diseases, such as the Zika virus, that have a high rate of Guillain-Barré Syndrome (GBS) are generally not good candidates for a vaccine, as the vaccine potentially can also cause GBS. GBS causes a severe form of paralysis and is considered a serious adverse event.
Pregnant women, infants and children are usually excluded from initial vaccine clinical trials, due to safety risks and are usually excluded from new vaccine development, due to unknown risks. A vaccine for Zika would not be initially approved for use in pregnant women and other at-risk populations, such as children and the elderly.
Antibody Dependent Enhancement (ADE) of either Zika or Dengue is a risk with a Zika Vaccine. Testing for this risk is going to be time consuming and costly.
Product Strategy
Atheric’s technology development began in late 2015, when Atheric’s founders recognized that the unmet medical need associated with the ZIKV epidemic in the Americas could only be addressed in a timely fashion by re-purposing existing licensed drugs. The majority of prior drug development strategies for flavivirus antivirals (including ZIKV) have primarily focused on single-agent therapeutic compounds. Atheric chose an alternative strategy, focusing on drugs and drug combinations which interfere with the interaction of flaviviruses with host cells: those which block the steps required for viral entry and infection of a cell, in which the virus subverts normal cellular processes to support viral replication. This combined approach, involving hypothesis-driven drug screening and prophylactic inhibition of host–virus interactions, together with selecting mixtures of drugs with complementary mechanisms of action, has allowed Atheric to rapidly identify antiviral drugs that are extremely potent.
Atheric’s strategy for antiviral drug screening is revolutionary. Atheric focuses on drugs and drug combinations which interfere with the interaction of viruses and host cells: drugs which block the steps required for viral entry, infection, and maturation of a cell, in which the virus subverts normal cellular processes to support viral replication. The combined approach, involving hypothesis-driven drug screening and inhibition of host–virus interactions, together with selecting mixtures of drugs with complementary mechanisms of action, has allowed Atheric to rapidly identify antiviral drugs that are highly potent.
There are no current preventions or treatments for diseases caused by ZIKV infections. ZIKV transmission routes include mosquitos and possibly other insect vectors, mother to fetus and child, men through sexual partners, and blood transfusion. ZIKV has spread to 48 countries and territories across the Americas, Oceania, the Pacific Islands, and Africa (CDC 2016), with over 1.5 million suspected and confirmed cases (WHO 2016). In the United States, sexually transmitted or travel-associated cases have been reported in 40 states as well as the District of Columbia. The Pan American Health Organization Zika incident commander estimates that 500 million people in the Americas are at risk for ZIKV infection (Samarasekera and Triunfol 2016). The World Health Organization estimates the lifetime U.S. costs associated with care for a microcephalic infant to be $10,000,000 (WHO 2016). In 1997, the USDA estimated the total cost of care for a case of GBS in the United States at $450,000 (Buzby, Roberts et al. 1997).
Atheric has rapidly identified many different re-purposed drug candidates by:
Understanding the cellular interactions that occur during ZIKV infection.
Using existing databases to identify repurposed drug candidates.
Screening and testing anti-viral activity in cultured cells using multiple viral isolates and sophisticated high-throughput multiplex imaging.
Identifying synergistic compound combinations.
Down-selecting compounds and compound combinations that are sufficiently bioavailable in humans based on pharmacometric modeling.
Animal testing for lead product candidate is underway (Zika).
Phase 1 PK studies as well as phase 2a clinical trial designs have been developed. The Pre-IND application has been submitted to the FDA (Zika).
Our lead anti-Zika product consists of the combination of a well-known anti-malarial drug with another well known anti-parasitic drug. Atheric’s strategy is to discover lead candidate antiviral drugs by determining in-vitro antiviral activity curves and then comparing these to the known BIOAVAILABILITY AND SAFETY OF THE DRUG(S) in patients. This is a critical step that is often missed by anti-viral drug developers who apply high throughput screening methods, and is one part of the process that makes the Atheric strategy dramatically different.
Funding and Partnering Opportunities:
Multiple partnering and licensing opportunities:
Opportunity to segment by geographic region, pathogen and indication.
Public-private-USG partnerships.
Direct wholesale marketing into developed market economies.
Partnering to sell into emerging market economies.
Atheric Pharmaceutical, LLC is a privately held corporation that seeks aligned stakeholders who share our vision of improving human health through the development of breakthrough medicines. We encourage interested parties to learn more about Atheric. For additional information contact our Corporate Development team.
[...]
Atheric Pharmaceutical, LLC is a privately held corporation that seeks aligned stakeholders who share our vision of improving human health through the development of breakthrough medicines. We encourage interested parties to learn more about Atheric. For additional information contact our Corporate Development team by sending us a message using the form below or calling 434-979-0090.
http://www.atheric.com/new-page-3
2017-05-atheric-com-newpage-3-zika-from-web-archive.pdf
Atheric Pharmaceutical LLC Factsheet
Executive Summary:
Atheric Pharmaceutical LLC (Atheric) is an early-stage pharmaceutical company focused on the prevention and treatment of human flavivirus disease (e.g., West Nile, dengue, yellow fever, and Zika virus (ZIKV)) including associated neurological disorders (e.g., Guillain–Barré Syndrome (GBS), congenital microcephaly) using repurposed multidrug broad spectrum antiviral pharmaceuticals. Atheric has several lead multidrug and backup combinations identified based on in situ multiplex screening (using cultured cells with different ZIKV isolates) combined with mechanism-based pharmacodynamic modeling using human population pharmacokinetic models. The market opportunity is that there are no medical countermeasures available for preventing or treating ZIKV infection and disease.
Product:
Atheric’s lead and backup multidrug combination products are repurposed multidrug broad spectrum antiviral pharmaceuticals. Key compounds are currently approved or recommended by various regulatory authorities for chronic administration during pregnancy for other indications, and cross the placenta enabling clinically significant pharmacodistribution to both mother and fetus. These compounds inhibit autophagy-dependent viral infection and replication, as well as other pathways associated with host-virus interactions. Other compounds are potent agents with more rapid clearance in the body, which are not contraindicated for use in pregnancy, and are suitable for short-term treatment and prophylaxis applications. The clinical indications Atheric is pursuing are:
1. Prevention of ZIKV-associated diseases, including GBS and other autoimmune and neuroinflammatory disorders in high-risk adults and travelers.
2. Prevention of Zika Fetal Syndrome (ZFS), including congenital microcephaly during pregnancy.
3. Ring containment of regional ZIKV infection outbreaks.
4. Treatment of currently infected patients, including men with potential to shed ZIKV in semen.
Intellectual Property (IP):
Atheric has filed 7 provisional patents (20-year exclusivity) filed with the USPTO. The likely claims are for repurposed individual drug compounds and multidrug combinations/formulations that are novel in both their new targets and new indications of use, methods and, in certain instances, compositions. The majority of these compounds are autophagy inhibitors that in vitro testing has demonstrated to have antiviral activity. Atheric will also pursue ex-U.S. IP rights.
Completed Developmental Milestones:
Atheric has several lead multidrug and backup combinations identified as a result of completing the following research activities:
I. Multiplex screening of identified compounds was performed using cultured cells (Vero E6, primary human fibroblasts, human astrocyte brain cells) with 2-hour drug pretreatment followed by infection with different ZIKV isolates representing African, Asian/Pacific, and American/Caribbean subtypes.
II. Multiple antimalarial and other licensed drugs that meet screening threshold criteria for anti-Zika activity were identified and further characterized.
III. In situ multiplex screening combined with mechanism-based pharmacodynamic modeling was then performed using human population pharmacokinetic models to predict and rationally optimize combination dosage regimens for human use.
IV. Preparing to test for potential anti-Zika activity in animals (e.g., murine AG129 mouse).
A draft manuscript currently under review by Science Translational Medicine provides a comprehensive review of and the rationale for Atheric’s R&D strategy and the above product development efforts, and is available upon request.
Collaboration Agreements:
Atheric is registered with the U.S. federal government’s System for Award Management (SAM):
I. BARDA – Atheric was the first organization invited to present medical countermeasure information through the TechWatch program to BARDA, and is well positioned to receive nondilutive capital once it is ready to begin clinical development.
II. USAMRIID – Atheric has executed Cooperative Research and Development Agreements (CRADAs) with USAMRIID, the lead laboratory of the Department of Defense (DoD) for medical biological defense research, for high-throughput screening and imaging.
III. NIAID – Atheric has executed a Non-Clinical Evaluation Agreement (NCEA) with the NIAID for compound-screening in animals.
Market Opportunity:
There are no current preventions or treatments for diseases caused by ZIKV infections. ZIKV transmission routes include mosquitos and possibly other insect vectors, mother to fetus and child, men through sexual partners, and blood transfusion. ZIKV has spread to 48 countries and territories across the Americas, Oceania, the Pacific Islands, and Africa (CDC 2016), with over 1.5 million suspected and confirmed cases (WHO 2016). In the United States, sexually transmitted or travel-associated cases have been reported in 40 states as well as the District of Columbia. The Pan American Health Organization Zika incident commander estimates that 500 million people in the Americas are at risk for ZIKV infection (Samarasekera and Triunfol 2016). The World Health Organization estimates the lifetime U.S. costs associated with care for a microcephalic infant to be $10,000,000 (WHO 2016). In 1997, the USDA estimated the total cost of care for a case of GBS in the United States at $450,000 (Buzby, Roberts et al. 1997).
https://twitter.com/naomirwolf/status/1720946974193549744
See new posts
Conversation
Dr Naomi Wolf
@naomirwolf
With Dr Jill Malone. Freedom fighters have more fun. Brownstone Gala, Dallas TX
7:31 PM · Nov 4, 2023
·
17.9K
Views
2023-11-04-twitter-com-naomirwolf-status-1720946974193549744.jpg
2023-11-04-twitter-com-naomirwolf-status-1720946974193549744-img-1.jpg
ANCESTRY RESEARCH
ANCESTRY RESEARCH
Name : Iris Glasspool / [Iris Britton]
Gender : Female
Race : White
Birth Date : 7 Jul 1920 ( Northampton, United Kingdom )
Death Date : 25 Feb 2007
Father : William J Britton
Mother: Elizabeth Barker
WIlliam THomas Glasspool (father) passed in 2003. No obituary can be found. https://www.ancestry.com/discoveryui-content/view/35225638:60901?tid=&pid=&queryId=b5b8ab608d5d6c0a21419d469f226a87&_phsrc=llt684&_phstart=successSource
https://www.newspapers.com/image/549236530/?match=1&terms=%22william%20glasspool%22
william glasspool manager special projects division raytheon
1967-07-12-the-cedar-rapids-gazette-pg-9d.jpg
1967-07-12-the-cedar-rapids-gazette-pg-9d-clip-raytheon.jpg
1978 (May 17)
Bid of 35,000 for San Marcos High School construction technology house
https://www.newspapers.com/image/931989554/?match=1&terms=%22william%20glasspool%22
2000 (Santa Maria times)
https://www.newspapers.com/image/446573008/?match=1&terms=%22william%20glasspool%22
issue with construction storage racks ?
2002-07-usa-gov-maryland-dep-business-economic-development-0190e.pdf
2002-07-usa-gov-maryland-dep-business-economic-development-0190e-img-pg-cover.jpg
2002-07-usa-gov-maryland-dep-business-economic-development-0190e-img-pg-27.jpg
Management Team
Dr. Martin Woodle
CEO and President
David Strickler
VP, Operations and Finance
Partrick Lu
Executive VP, Genomics
Dr. Puthupparampil Scaria
VP, Synthetic Vectors
Casimir Eitner
Chief Business Officer
Intradigm Corporation www.intradigm.net
Rockville, MD MD Employees: 13
Other Co-Investors
Emerging Technology Partners
Novartis Venture Fund
Cost to State of Maryland
$300,000
Current Fair Market Value
$300,000
History
Intradigm was founded in mid-
2000 by Ms. Jill Glasspool-
Malone, Dr. Jim Mixson, and Dr.
Martin Woodle. Novartis originally
owned the non-viral gene delivery
technology, which was developed
at Genetic Therapy, Inc., but
decided against continuing R&D
efforts. The license agreement
transferred contingent on funding
from Emerging Technology
Partners and Novartis’ own venture
fund.
Products
Intradigm Corporation is focused
on exploiting its proprietary target
discovery and validation technologies
to develop new therapeutics
for cancer, arthritis and other
critical care indications.
Intradigm’s approach is unique in
that it rapidly discovers and discriminates
the proteins that control
disease as distinguished from
those that only correlate with disease.
Disease-control validation
of targets enables drug development
based on target efficacy
reducing costs and improving the
success rate. Intradigm does this
by exploiting its leading expertise
in gene delivery in animals to
over-express protein targets
and/or to silence them with RNAi
directly in animal models of disease.
Intradigm’s method skips
slow and expensive validation
steps by operating directly in the
active disease tissues rapidly
revealing which proteins provide
efficacy.
Competition
The competitors to Intradigm
include commercial entities and
academic laboratories. The commercial
entities span small to
established Biotech companies
(such as Copernicus in
Cincinnati, Ohio, Targeted
Genetics Inc. in Seattle,
Washington, TransGene in
Strasbourg, France, Valentis
Inc. in Burlingame, California,
Genzyme Inc. in Cambridge,
Massachusetts, Cell Genesis in
Foster City, California, and
Amgen in Thousand Oaks,
California), and divisions of large
pharmaceutical companies (such
as GenCell division of Aventis). In
addition, a number of academic
laboratories worldwide are working
to develop new technology for
polynucleotide delivery and gene
therapy. The in vivo genomics target
identification and validation
business faces very little competition.
Most in vivo gene delivery
vector development efforts are
proceeding solely for therapeutic
applications. Intradigm is establishing
a business method patent
for this application to protect it
from such competition.
Events
Intradigm closed on its Series A
round of funding in June 2001.
Robert Riley was elected to the
Board of Directors.
Intradigm signed an agreement
with Direct Gene to provide the
delivery technology to improve
Direct Gene’s product.
The company is currently raising
its Series B round of funding.
Page updated
Report abuse